AVTRHealthcare · Medical Instruments & SuppliesThe 16 Wall Street analysts covering Avantor, Inc. hold a median 12-month price target of $14 — +6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 17 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Avantor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (95): Analysts have, on balance, been raising their forecasts.
Growth (38): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVTR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +6.5% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Evercore ISI Group | Maintains | In-Line | $11 → $14 |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $10 → $14 |
| 30 July 2026 | RBC Capital | Maintains | Sector Perform | $9.00 → $14 |
| 30 July 2026 | Stifel | Maintains | Hold | $8.00 → $15 |
| 30 July 2026 | Wells Fargo | Maintains | Overweight | $14 → $16 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $9.00 → $11 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | $8.00 → $11 |
| 6 July 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 26 June 2026 | Bernstein | Reinstates | Market Perform | $11 |
| 24 June 2026 | Barclays | Maintains | Underweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Underperform | $7.00 |
| 15 May 2026 | RBC Capital | Reinstates | Sector Perform | $9.00 |
| 30 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 30 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 15 Apr 2026 | Barclays | Maintains | Underweight | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | In-Line | — |
| 6 Mar 2026 | Barclays | Downgrade | Underweight | — |
| 13 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 12 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 47% of US stocks
Cheaper than 63% of US stocks
Cheaper than 54% of US stocks
Cheaper than 28% of US stocks
Higher than 29% of US stocks
Higher than 12% of US stocks
Higher than 37% of US stocks
Higher than 59% of US stocks
Higher than 21% of US stocks
Higher than 36% of US stocks
Higher than 63% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Avantor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Investment Research report compares the year-to-date performance of Avantor (AVTR) and Johnson & Johnson (JNJ) relative to their sector.
Why it matters — AVTR watchers would care because the piece situates Avantor's performance this year within the broader medical sector context and against a major peer.
Zacks Investment Research noted that Avantor's (AVTR) 50-day simple moving average recently crossed above its 200-day moving average, a technical pattern known as a "golden cross," indicating the stock reached a significant support level.
Why it matters — A golden cross is viewed by some technical traders as a bullish signal, and the item highlights AVTR's price action at a key support level.
Avantor reported second-quarter earnings and revenue that beat analyst estimates, driven by an earlier-than-expected return to organic growth at VWR. The company also raised its revenue and earnings guidance for 2026.
Why it matters — An earnings beat coupled with higher forward guidance signals improving operational momentum, particularly from the VWR segment, which is a key growth driver for Avantor.
Avantor reported second-quarter 2026 results that surpassed expectations, driven by a return to organic growth in its VWR Distribution & Services segment, strong free cash flow, and progress under its Revival operational improvement program.
Why it matters — The results indicate that Avantor's operational improvement initiatives are gaining traction and that its core distribution segment is returning to organic growth.
A broad market sell-off deepened Wednesday as crude oil spiked 7% on fresh U.S.-Iran tensions ahead of the Federal Reserve's rate decision, dragging the S&P 500 to four-week lows and pushing the Nasdaq 100 more than 10% below its prior records.
Why it matters — As a life-sciences tools and supplies company, Avantor's stock is exposed to broad market sell-offs and macroeconomic shocks like oil price spikes and geopolitical escalation that can pressure equity valuations across sectors.
The 16 Wall Street analysts covering Avantor, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Avantor, Inc., 3 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Avantor, Inc. 79 out of 100 across roughly 4,600 US stocks as at 17 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 17 Aug 2026, Avantor, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +6.5% from the last close, and Ticker Nerd's factor model ranks Avantor, Inc. 79 out of 100 as at 17 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Avantor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $19 over the next 12 months.
Avantor, Inc. returned +4.5% over the 12 months to 18 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Avantor Inc. is a global life sciences and advanced technology products and services company that supplies mission-critical materials to laboratories, biopharma manufacturers, healthcare organizations, educational institutions, government customers, and industrial users.
The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Are Medical Stocks Lagging Avantor (AVTR) This Year?". A Zacks Investment Research report compares the year-to-date performance of Avantor (AVTR) and Johnson & Johnson (JNJ) relative to their sector.
Avantor Inc. is a global life sciences and advanced technology products and services company that supplies mission-critical materials to laboratories, biopharma manufacturers, healthcare organizations, educational institutions, government customers, and industrial users. The company’s portfolio includes laboratory chemicals, reagents, consumables, equipment, instrumentation, and specialty procurement services used across research, quality control, and production workflows. Its bioscience production offerings support bioprocessing with high-purity materials, single-use technologies, and related solutions designed for regulated manufacturing environments. Avantor also serves advanced technologies and applied materials markets with products used in semiconductor, electronics, and other precision applications. Headquartered in Radnor, Pennsylvania, Avantor plays a broad role in the scientific supply chain by helping customers source the products and services needed from discovery through scale-up and production.
CEO Mr. Emmanuel Ligner · 13,500 employees · United States · https://www.avantorsciences.com